From: Woolley, Dr Jane
Sent: 22 February 2017 14:46

To:

**Subject:** RE: FW: VigiBase Program - Finasteride

Hi

To be honest, as we are not able to help him and he will never be happy until the drug is off the market I have suggested paring this right back to the minimum. You've already expressed sympathy in previous emails, he didn't know the victim personally as far as I know, any kind of official expression of sympathy often goes unbelieved, and he might be annoyed that we're asking him to do more for us when he will perceive that we haven't helped him.

Obviously if it makes you feel better to go with the original version do feel free.

Thanks Jane

**From:** on **Sent:** 22 February 2017 14:12

To: Woolley, Dr Jane

Subject: FW: FW: VigiBase Program - Finasteride ADR

How about this?

Thank you for your further email.


I am unable to access Facebook pages so if there are details which you can provide that I can follow up for further information, please do not hesitate to contact me.


In the meantime I will let you know further as it becomes available to me. I am unable to give you further information news on finasteride at present but will do so as soon as I am able.

Kind regards





From: Yellow Card Mailbox Sent: 21 February 2017 11:19 To: Cc: Yellow Card Mailbox
Subject: FW: FW: VigiBase Program - Finasteride ADR
Hi en
Just to confirm I have logged the below query and have transferred the case to you also mentioned another case in the email below regarding another patient being affected, can you let unknow whether or not it should be logged as a yellow card?
Thank you, Kind Regards,
Vigilance and Risk Management of Medicines Division
Medicines and Healthcare Products Regulatory Agency 151 Buckingham Palace Road, London, SW1W 9SZ Email: <u>pharmacovigilanceservice@mhra.gsi.gov.uk</u> Stay connected: mhra.gov.uk/stayconnected













































Kind regards,
Yellow Card (Side Effects) Service Team
Vigilance and Risk Management of Medicines Division
Medicines and Healthcare Products Regulatory Agency
151 Buckingham Palace Road, London, SW1W 9SZ
Email:
yellow.card@mhra.gsi.gov.uk
Stay connected:
mhra.gov.uk/stayconnected

From:
<b>Sent:</b> 09 September 2015 17:59
To: Raine, Dr June
Subject: VigiBase Program - Finasteride ADR
Dear Dr. June Raine



This email was scanned by the Government Secure Intranet anti-virus service supplied by Vodafone in partnership with Symantec. (CCTM Certificate Number 2009/09/0052.) In case of problems, please call your organisations IT Helpdesk.
Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.
This email and any files transmitted with it are  confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful.
If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications.
For more information on the Department of Health's email policy, click
<b>DHTermsAndConditions</b>

The original of this email was scanned for viruses by the Government Secure Intranet virus scanning service supplied by Vodafone in partnership with Symantec. (CCTM Certificate Number 2009/09/0052.) This email has been certified virus free.
Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.
This email has been scanned by the Symantec Email Security.cloud service.
This chian has been scanned by the Symanice Email Security. Cloud service.
For more information please visit
http://www.symanteccloud.com

This email has been scanned by the Symantec Email Security.cloud service.

For more info	rmation please visit
http://www.sy	rmanteccloud.com
his email has	been scanned by the Symantec Email Security.cloud service.
inis cinan nas	been seamed by the symantee Email security.cloud service.
For more infor	mation please visit
nttp://www.syr	manteccloud.com
This amail has	been scanned by the Symantec Email Security.cloud service.
illis eman nas	been scanned by the Symantec Eman Security. Cloud service.
For more infor	mation please visit <a href="http://www.symanteccloud.com">http://www.symanteccloud.com</a>
his email has h	been scanned by the Symantec Email Security.cloud service.

This email has been scanned by the Symantec Email Security.cloud service. For more information please visit <a href="http://www.symanteccloud.com">http://www.symanteccloud.com</a>